130 related articles for article (PubMed ID: 20665381)
1. A patient with chronic hepatitis B and regression of fibrosis during treatment.
Chang CY; Martin P; Fotiadu A; Hytiroglou P
Semin Liver Dis; 2010 Aug; 30(3):296-301. PubMed ID: 20665381
[TBL] [Abstract][Full Text] [Related]
2. Correlation of hepatocyte expression of hepatitis B viral antigens with histological activity and viral titer in chronic hepatitis B virus infection: an immunohistochemical study.
Ramakrishna B; Mukhopadhya A; Kurian G
J Gastroenterol Hepatol; 2008 Nov; 23(11):1734-8. PubMed ID: 18713304
[TBL] [Abstract][Full Text] [Related]
3. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Sponseller CA; Bacon BR; Di Bisceglie AM
Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
[TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
[TBL] [Abstract][Full Text] [Related]
7. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.
Xu B; Lin L; Xu G; Zhuang Y; Guo Q; Liu Y; Wang H; Zhou X; Wu S; Bao S; Cai W; Xie Q
J Gastroenterol Hepatol; 2015 Feb; 30(2):372-8. PubMed ID: 25167956
[TBL] [Abstract][Full Text] [Related]
8. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
9. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
Chang TT; Liaw YF; Wu SS; Schiff E; Han KH; Lai CL; Safadi R; Lee SS; Halota W; Goodman Z; Chi YC; Zhang H; Hindes R; Iloeje U; Beebe S; Kreter B
Hepatology; 2010 Sep; 52(3):886-93. PubMed ID: 20683932
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis B in Asia-new insights from the past decade.
Chan HL; Jia J
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():131-7. PubMed ID: 21199524
[TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.
Lim SG; Ng TM; Kung N; Krastev Z; Volfova M; Husa P; Lee SS; Chan S; Shiffman ML; Washington MK; Rigney A; Anderson J; Mondou E; Snow A; Sorbel J; Guan R; Rousseau F;
Arch Intern Med; 2006 Jan; 166(1):49-56. PubMed ID: 16401810
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs.
Brown A; Goodman Z
Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):187-98. PubMed ID: 22375524
[TBL] [Abstract][Full Text] [Related]
13. e-antigen-negative chronic hepatitis B in Bangladesh.
Ahmad N; Alam S; Mustafa G; Adnan AB; Baig RH; Khan M
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):379-82. PubMed ID: 18693173
[TBL] [Abstract][Full Text] [Related]
14. Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B.
Mihm U; Sarrazin C; Herrmann E; Teuber G; von Wagner M; Kronenberger B; Zeuzem S
Z Gastroenterol; 2003 Mar; 41(3):249-54. PubMed ID: 12664345
[TBL] [Abstract][Full Text] [Related]
15. To stop or not to stop: the quest for long-term viral suppression.
Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2011 Mar; 26(3):420-2. PubMed ID: 21332537
[No Abstract] [Full Text] [Related]
16. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
17. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
Chen JJ; Wang ZH; Ma SW; Chen YP; Peng J; Guo YB; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
[TBL] [Abstract][Full Text] [Related]
18. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.
Borgniet O; Parvaz P; Bouix C; Chevallier P; Trépo C; André P; Zoulim F
J Med Virol; 2009 Aug; 81(8):1336-42. PubMed ID: 19551826
[TBL] [Abstract][Full Text] [Related]
19. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
[TBL] [Abstract][Full Text] [Related]
20. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
